All News #Library
Biotech
Akamis Bio Announces NG-350A FORTRESS Results for Rectal Cancer
17 Apr 2026 //
FIRSTWORD PHARMA
Akamis Bio Granted FDA Fast Track For NG-350A In Rectal Cancer
14 Oct 2025 //
BUSINESSWIRE
Akamis Bio Enrolls 1st Patient in Phase 1b FORTRESS Trial of NG-350A
03 Apr 2025 //
BUSINESSWIRE
Akamis Bio Strengthens Leadership Team with Key Executive Appointments
06 Jul 2023 //
BUSINESSWIRE

Market Place
Sourcing Support